Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 5/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20315041 | 0.91 | GABRA1 (0.45) | GABRA1GABRB2ADRB2ADRB1ADRB3 | |
| SCHEMBL15631290 | 0.88 | ADRA1A (0.54) | GABRA1GABRB2ADRB2ADRB1ADRB3 | |
| SCHEMBL16736936 | 0.86 | LMNA (0.47) | GABRA1GABRB2ADRB2ADRB1ADRB3 | |
| SCHEMBL20780493 | 0.86 | LMNA (0.47) | GABRA1GABRB2ADRB2ADRB1ADRB3 | |
| SCHEMBL12173270 | 0.84 | EIF4A3 (0.42) | GABRA1GABRB2ADRB2ADRB1ADRB3 | |
| SCHEMBL23434932 | 0.83 | LMNA (0.48) | GABRA1GABRB2ADRB2ADRB1ADRB3 | |
| SCHEMBL20711875 | 0.82 | LMNA (0.48) | GABRA1GABRB2ADRA1ACYP3A4HSD17B10 | |
| SCHEMBL12172238 | 0.82 | LMNA (0.44) | GABRA1GABRB2ADRB2ADRB1ADRB3 | |
| SCHEMBL14629520 | 0.80 | GABRA1 (0.43) | GABRA1GABRB2ADRB2ADRB1ADRB3 | |
| SCHEMBL1911426 | 0.79 | EIF4A3 (0.40) | GABRA1GABRB2ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968205-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200216423-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-07-09 | — | — | US | disclosed |
| US-10538513-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-01-21 | — | — | US | disclosed |
| US-20190315724-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-17 | — | — | US | disclosed |
| US-10392368-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190040043-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-07 | — | — | US | disclosed |
| US-7202359-B2 | Azaoxa heterocyclic compound and method of preparing the same | CHANG CHUN PLASTICS CO., LTD. (TW) | 2007-04-10 | — | — | US | disclosed |
| CN-1234706-C | Nitrogen-oxygen heterocyclic compound and preparation method thereof | CHANGCHUN ARTIFICIAL RESIN FAC (CN) | 2006-01-04 | — | — | CN | disclosed |
| US-20050085634-A1 | Azaoxa heterocyclic compound and method of preparing the same | CHANG CHUN PLASTICS CO., LTD. (TW) | 2005-04-21 | — | — | US | disclosed |
| US-20040254305-A1 | Epoxy resin composition for photosemiconductor package | CHANG CHUN PLASTIC CO., LTD. (TW) | 2004-12-16 | — | — | US | disclosed |
| CN-1490318-A | Nitrogen-oxygen heterocyclic compound and preparation method thereof | 长春人造树脂厂股份有限公司 | 2004-04-21 | — | — | CN | disclosed |
| US-20040068084-A1 | Azaoxa heterocyclic compound and method of preparing the same | CHANG CHUN PLASTICS CO., LTD. (TW) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040068084-A1 | Azaoxa heterocyclic compound and method of preparing the same | AOX1, KDM1A, BMI1 | GABRA1 690/4885GABRB2 1324/4885ADRB2 3171/4885 |
| US-20190315724-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | GABRA1 1987/4885GABRB2 3026/4885ADRB2 3688/4885 |
| US-10968205-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | JAK3, JAK1, JAK2 | GABRA1 1987/4885GABRB2 3026/4885ADRB2 3688/4885 |
| US-20190040043-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | GABRA1 1987/4885GABRB2 3026/4885ADRB2 3688/4885 |
| US-10392368-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | JAK3, JAK1, JAK2 | GABRA1 1987/4885GABRB2 3026/4885ADRB2 3688/4885 |
| US-20050085634-A1 | Azaoxa heterocyclic compound and method of preparing the same | AOX1, KDM1A, BMI1 | GABRA1 688/4885GABRB2 1173/4885ADRB2 3118/4885 |
| US-20200216423-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | GABRA1 1987/4885GABRB2 3026/4885ADRB2 3688/4885 |
| US-10538513-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | JAK3, JAK1, JAK2 | GABRA1 1987/4885GABRB2 3026/4885ADRB2 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.